Zhitong Financial APP learned thatGovernorofpoker2Announced on SaturdayGovernorofpoker2In a large placebo-controlled study, Danish pharmaceutical giant NVOGovernorofpoker2The "slimming pill" launched by Smeglu has significantly reduced kidney-related adverse events in obese and overweight people by 22%. The analysis is based on the company's SELECT international trial, which tested 2 of Wegovy (the official trade name of Smeagralopeptide)Governorofpoker2.4 the mg dose, compared with the placebo control group, covered more than 17000 overweight or obese adults as an additional supplement to the standard care control.
Professor Helen Colhorn of the University of Edinburgh, who is understood to be the lead author of the blockbuster study, presented the findings at the European Kidney Congress in Stockholm on Saturday.
"by addressing key indicators of kidney health, Smegler may help significantly reduce the risk of all kidney-related complications, including chronic kidney disease and end-stage kidney disease."
It is understood that the pharmaceutical giant from Denmark has well documented the kidney benefits of Smegler in the past. As early as March this year, the company said that a dose of GLP-1 receptor agonist 1.0 mg combined with standard care significantly reduced the risk of major kidney disease-related events in patients with type 2 diabetes and chronic kidney disease by 24%.
Novo and its strongest competitor in weight-loss drugs, Eli Lilly, are also testing its weight-loss drug tirzepatide, which treats kidney-related diseases, and its shares fell after the announcement of Novo Nord's weight-loss benefits for the kidneys.
A Novo Nord spokesman was quoted by the media as saying that the latest data "demonstrate for the first time the new benefits of 2.4 mg doses of Smegrupetide in improving kidney function in people at high risk of cardiovascular disease, overweight or obesity, and non-diabetes, who have a significantly increased demand for kidney protection."
As early as last August, the company said that a SELECT study aimed at assessing the benefits of Simigelutide on the human heart had met its main goal of reducing adverse cardiovascular risk events such as stroke by 20 per cent once a week.
According to the latest survey data released by well-known health research agency KFF, one in eight American adults has tried fast-growing new diabetes and anti-obesity drugs, including Novo Nord's Ozempic and Lilly's Zepbound. The KFF survey also shows that about half of those who have tried to inject the weight-loss drug are still taking it. The new poll, conducted at the end of April, sampled nearly 1500 adults online and over the phone in English and Spanish.
Mounjaro and Zepbound, weight-loss drugs owned by US pharmaceutical giant LLY.US, and drugs such as Ozempic and Wegovy, owned by Danish pharmaceutical giant NVO.US, are reaching Americans, where the incidence of diabetes and obesity has been rising steadily for decades.
The market for such slimming drugs is expected to reach at least $80 billion by 2030, according to Bloomberg Intelligence research. Wall Street giant Goldman Sachs is more optimistic, with a forecast by Goldman Sachs that annual sales of the global anti-obesity drug market could grow to about $100 billion by 2030, compared with $6 billion in early 2023. The World Obesity Federation (WOF) estimates that more than 4 billion people (more than half of the world's population) may be obese to varying degrees by 2035.